Phase 3 Readout~month

Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada

Indication
Anemia of Chronic Kidney Disease

Other upcoming events for AKBA

Patent ExpiryPatent/Exclusivity Expiry: AURYXIA
Patent ExpiryPatent/Exclusivity Expiry: VAFSEO

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vada — AKBA Phase 3 Readout | BioSniper